Nature Medicine 发布 Toripalimab 联合化疗一线治疗晚期鼻咽癌 III 期研究作者更正
Author Correction: Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial
Nature Medicine 发布 Toripalimab 或安慰剂联合化疗一线治疗晚期鼻咽癌的多中心随机 III 期试验作者更正。该研究由中山大学肿瘤防治中心等机构参与，作者单位信息得到更新。
These authors contributed equally: Hai-Qiang Mai, Qiu-Yan Chen.
Department of Nasopharyngeal Carcinoma, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China
Hai-Qiang Mai & Qiu-Yan Chen
Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China
Dongping Chen
Fudan University Cancer Center, Shanghai, China
Chaosu Hu
Union Hospital Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Kunyu Yang
Affiliated Hospital of Guangdong Medical University, Zhanjiang, China
Jiyu Wen
Jiangxi Cancer Hospital, Nanchang, China
Jingao Li
Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, China
Ying-Rui Shi
Guizhou Cancer Hospital of Guizhou Medical University, Guiyang, China
Feng Jin
Shenzhen People’s Hospital, Shenzhen, China
Ruilian Xu
Fujian Provincial Cancer Hospital, Fuzhou, China
Jianji Pan
The People’s Hospital of Guangxi Zhuang Autonomous Region, Nanning, China
Shenhong Qu
West China Hospital of Sichuan University, Chengdu, China
Ping Li
The Second Xiangya Hospital of Central South University, Changsha, China
Chunhong Hu
Taichung Veterans General Hospital, Taichung, Taiwan
Yi-Chun Liu
Cancer Hospital of Shantou University Medical College, Shantou, China
Yi Jiang
Jiangsu Cancer Hospital, Nanjing, China
Xia He
Chang Gung Memorial Hospital, Taoyuan, Taiwan
Hung-Ming Wang
National Cancer Centre, Singapore City, Singapore
Wan-Teck Lim
Nanfang Hospital, Guangzhou, China
Wangjun Liao
Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Xiaohui He
Zhejiang Cancer Hospital, Hangzhou, China
Xiaozhong Chen
The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, China
Zhigang Liu
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Xianglin Yuan
Shanghai General Hospital, Shanghai, China
Qi Li
Fujian Medical University Union Hospital, Fuzhou, China
Xiaoyan Lin
The Fourth Hospital of Hebei Medical University Hebei Cancer Hospital, Shijiazhuang, China
Shanghua Jing
Hainan General Hospital, Haikou, China
Yanju Chen
Liuzhou Worker’s Hospital, Liuzhou, China
Yin Lu
China Medical University Hospital, Taichung, Taiwan
Ching-Yun Hsieh
Taipei Veterans General Hospital, Taipei, Taiwan
Muh-Hwa Yang
National Cheng Kung University, Tainan, Taiwan
Chia-Jui Yen
Tan Tock Seng Hospital, Singapore City, Singapore
Jens Samol
Johns Hopkins University, Baltimore, MD, USA
Jens Samol
Shanghai Junshi Biosciences, Shanghai, China
Hui Feng & Sheng Yao
TopAlliance Biosciences, Rockville, MD, USA
Hui Feng, Sheng Yao & Patricia Keegan
Department of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China
Rui-Hua Xu
来源：Nature Medicine · nature.com